Loading...
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.
Cunningham, D Stenning, S Smyth, E Okines, A Allum, W Rowley, S Stevenson, L Grabsch, H Alderson, D Crosby, T
Cunningham, D
Stenning, S
Smyth, E
Okines, A
Allum, W
Rowley, S
Stevenson, L
Grabsch, H
Alderson, D
Crosby, T
Citations
Altmetric:
Abstract
Peri-operative chemotherapy and surgery is a standard of care for patients with resectable oesophagogastric adenocarcinoma. Bevacizumab, a monoclonal antibody against VEGF, improves the proportion of patients responding to treatment in advanced gastric cancer. We aimed to assess the safety and efficacy of adding bevacizumab to peri-operative chemotherapy in patients with resectable gastric, oesophagogastric junction, or lower oesophageal adenocarcinoma.
Description
Date
2017-02-02
Publisher
Collections
Files
Keywords
Type
Article
Citation
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. 2017, Lancet Oncol